losartan has been researched along with Left Ventricular Dysfunction in 50 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 9.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| "The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension (J-ELAN) study is a multicenter, prospective, randomized trial designed to assess the effects of losartan and amlodipine on LV diastolic function in hypertensive patients with LV diastolic dysfunction in the absence of systolic dysfunction." | 9.12 | Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. ( , 2006) |
| "Treatment with losartan increased left ventricular ejection fraction (baseline vs." | 6.71 | Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure. ( Hisatome, I; Igawa, O; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2004) |
| "To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy." | 5.16 | Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 5.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| " We also studied whether long-term treatment with isosorbide-5-mononitrate (IS-5-MN) in combination with standard HF therapy affects P-MDA levels in patients with evidence of left ventricular (LV) dysfunction following acute myocardial infarction (AMI)." | 5.12 | Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy. ( Gottsäter, A; Ohlin, AK; Ohlin, H; Tingberg, E, 2006) |
| "The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension (J-ELAN) study is a multicenter, prospective, randomized trial designed to assess the effects of losartan and amlodipine on LV diastolic function in hypertensive patients with LV diastolic dysfunction in the absence of systolic dysfunction." | 5.12 | Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. ( , 2006) |
| "The OPTIMAAL trial randomized 5477 patients with heart failure or evidence of left ventricular dysfunction following acute MI to losartan or captopril." | 5.11 | Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. ( Cleland, JG; Dickstein, K; Kjekshus, J; Orn, S; Romo, M, 2005) |
| "Twenty patients with moderately severe chronic heart failure received enalapril 10 mg and losartan 50 mg on 2 separate occasions in a single-blind, randomized, crossover design." | 5.09 | Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. ( Flapan, AD; Goodfield, NE; Ludlam, CA; Newby, DE, 1999) |
| "The randomized angiotensin receptor antagonist--angiotensin converting enzyme (ACE)--Inhibitor Study (RAAS) was designed to test the hypothesis that the addition of an angiotensin II type 1 receptor blocking agent, losartan 50 mg/day, to an ACE-inhibitor, enalapril 10 mg twice a day (group 1), will be more effective than standard-dose enalapril 10 mg twice a day (group 2) or high-dose enalapril alone 20 mg twice a day (group 3), in blocking the activation of the renin angiotensin aldosterone system in patients with heart failure and left ventricular systolic dysfunction." | 5.08 | Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS). ( Chang, P; Dunlay, M; Grossman, W; Pitt, B; Timmermans, PB, 1996) |
| " The angiotensin II antagonist losartan, metabolized to the EXP3179 and EXP3174 metabolites, reduces myocardial fibrosis and LV stiffness in hypertensive patients." | 3.85 | Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. ( Beaumont, J; Díez, J; Fortuño, A; González, A; López, B; Miguel-Carrasco, JL; Moreno, MU; Ravassa, S; San José, G; Zalba, G, 2017) |
| "The activation of angiotensin II type 1 receptor (AT1R) in the brain plays a pivotal role in enhanced sympathetic drive in heart failure (HF)." | 3.77 | Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure. ( Hirooka, Y; Kishi, T; Ogawa, K; Sunagawa, K, 2011) |
| "Hypertensive patients who had not achieved their target blood pressure with at least 4 weeks of ARB therapy were randomly assigned to receive either a fixed-dose combination of losartan and HCTZ (losartan/HCTZ; n=110) or a combination of amlodipine and a typical ARB dosage (CCB/ARB; n=121) and followed for 24 weeks." | 2.82 | Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients. ( Ishii, K; Ito, H; Iwakura, K; Kihara, H; Toh, N; Watanabe, H; Yoshikawa, J, 2016) |
| "Hypertension is associated with an increased risk of diastolic dysfunction." | 2.77 | Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension. ( Fukuda, S; Ishii, K; Ito, H; Iwakura, K; Kasayuki, N; Kihara, H; Nakamura, F; Shimada, K; Yoshikawa, J, 2012) |
| "Treatment with losartan increased left ventricular ejection fraction (baseline vs." | 2.71 | Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure. ( Hisatome, I; Igawa, O; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2004) |
| "Risk of stroke was increased for the first 30 days (HR 14." | 2.71 | Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. ( Dickstein, K; Lehto, M; Nieminen, MS; Snapinn, S; Swedberg, K, 2005) |
| "Losartan treatment had no impact on growth or kidney development." | 1.43 | Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction. ( Béland-Bonenfant, S; Bertagnolli, M; Cloutier, A; Dios, A; Gascon, G; Lukaszewski, MA; Nuyt, AM; Paradis, P; Schiffrin, EL; Sutherland, M, 2016) |
| "Treatment with losartan reduced left ventricular dysfunction and prevented increased extracellular volume fraction, indicating that T1 mapping is sensitive to pharmacological prevention of fibrosis." | 1.40 | T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy. ( Fiedler, LR; Gsell, W; Habib, J; McSweeney, SJ; Prasad, SK; Price, AN; Schneider, MD; Stuckey, DJ; Thin, MZ, 2014) |
| " These results indicate that effects on cardiac load by peripheral AT(1) receptor blockade or the pharmacokinetic profile of subcutaneous versus oral dosing do not contribute to the different cardiac effects of central versus systemic AT(1) receptor blockade post-MI." | 1.35 | Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction. ( Ahmad, M; Huang, BS; Leenen, FH; Tan, J, 2009) |
| "Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| "Losartan was given in drinking water to 13 Dahl S and 13 Dahl R rats, while 14 control Dahl S and 14 control Dahl R rats were given tap water, for 8 weeks." | 1.29 | Midwall left ventricular performance in salt-loaded Dahl rats: effect of AT1 angiotensin II inhibition. ( Camargo, MJ; de Simone, G; Devereux, RB; Laragh, JH; Sealey, JE; Wallerson, DC, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (14.00) | 18.2507 |
| 2000's | 28 (56.00) | 29.6817 |
| 2010's | 13 (26.00) | 24.3611 |
| 2020's | 2 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yokota, T | 1 |
| Koiwa, H | 1 |
| Matsushima, S | 1 |
| Tsujinaga, S | 1 |
| Naya, M | 1 |
| Morisaki, H | 1 |
| Morisaki, T | 1 |
| Akazawa, Y | 1 |
| Fujioka, T | 1 |
| Ide, H | 1 |
| Yazaki, K | 1 |
| Honjo, O | 1 |
| Sun, M | 1 |
| Friedberg, MK | 1 |
| Zheng, M | 1 |
| Pan, F | 1 |
| Liu, Y | 1 |
| Li, Z | 1 |
| Zhou, X | 1 |
| Meng, X | 1 |
| Liu, L | 1 |
| Ge, S | 1 |
| Stuckey, DJ | 1 |
| McSweeney, SJ | 1 |
| Thin, MZ | 1 |
| Habib, J | 1 |
| Price, AN | 1 |
| Fiedler, LR | 1 |
| Gsell, W | 1 |
| Prasad, SK | 1 |
| Schneider, MD | 1 |
| Toh, N | 1 |
| Ishii, K | 2 |
| Kihara, H | 2 |
| Iwakura, K | 2 |
| Watanabe, H | 1 |
| Yoshikawa, J | 2 |
| Ito, H | 3 |
| Bertagnolli, M | 1 |
| Dios, A | 1 |
| Béland-Bonenfant, S | 1 |
| Gascon, G | 1 |
| Sutherland, M | 1 |
| Lukaszewski, MA | 1 |
| Cloutier, A | 1 |
| Paradis, P | 1 |
| Schiffrin, EL | 1 |
| Nuyt, AM | 1 |
| Miguel-Carrasco, JL | 1 |
| Beaumont, J | 1 |
| San José, G | 1 |
| Moreno, MU | 1 |
| López, B | 2 |
| González, A | 2 |
| Zalba, G | 1 |
| Díez, J | 2 |
| Fortuño, A | 1 |
| Ravassa, S | 1 |
| Maczewski, M | 1 |
| Maczewska, J | 1 |
| Duda, M | 1 |
| Tepliakov, AT | 1 |
| Maianskaia, SD | 1 |
| Bolotskaia, LA | 1 |
| Vdovina, TV | 1 |
| Stepacheva, TA | 1 |
| Kuznetsova, AV | 1 |
| Lukinov, AV | 1 |
| Derbeneva, NV | 1 |
| Frants, MV | 1 |
| Shilov, SN | 1 |
| Huang, BS | 1 |
| Ahmad, M | 1 |
| Tan, J | 1 |
| Leenen, FH | 2 |
| Yoshida, C | 1 |
| Goda, A | 1 |
| Naito, Y | 1 |
| Nakaboh, A | 1 |
| Matsumoto, M | 1 |
| Otsuka, M | 1 |
| Ohyanagi, M | 1 |
| Hirotani, S | 1 |
| Lee-Kawabata, M | 1 |
| Tsujino, T | 1 |
| Masuyama, T | 1 |
| Eklind-Cervenka, M | 1 |
| Benson, L | 1 |
| Dahlström, U | 1 |
| Edner, M | 1 |
| Rosenqvist, M | 1 |
| Lund, LH | 1 |
| Maejima, Y | 1 |
| Nobori, K | 1 |
| Ono, Y | 1 |
| Adachi, S | 1 |
| Suzuki, J | 1 |
| Hirao, K | 1 |
| Isobe, M | 1 |
| Volpe, M | 1 |
| Taddei, S | 1 |
| Fruhwald, F | 1 |
| Pieske, B | 1 |
| Fogari, R | 1 |
| Mugellini, A | 1 |
| Destro, M | 1 |
| Corradi, L | 1 |
| Lazzari, P | 1 |
| Zoppi, A | 1 |
| Preti, P | 1 |
| Derosa, G | 1 |
| Ogawa, K | 1 |
| Hirooka, Y | 1 |
| Kishi, T | 1 |
| Sunagawa, K | 1 |
| Kasayuki, N | 1 |
| Nakamura, F | 1 |
| Shimada, K | 1 |
| Fukuda, S | 1 |
| Pascual Figal, DA | 1 |
| Morena Valenzuela, Gde L | 1 |
| Nicolás Ruiz, F | 1 |
| Tovar Zapata, I | 1 |
| Ruipérez Abizanda, JA | 1 |
| Valdés Chávarri, M | 1 |
| Shinohara, H | 1 |
| Fukuda, N | 1 |
| Soeki, T | 1 |
| Sakabe, K | 1 |
| Onose, Y | 1 |
| Tamura, Y | 1 |
| Danchin, N | 1 |
| Kubota, T | 1 |
| Takeshita, A | 1 |
| Lapointe, N | 1 |
| Pourdjabbar, A | 1 |
| Rouleau, JL | 1 |
| Umemoto, S | 1 |
| Kawahara, S | 1 |
| Hashimoto, R | 1 |
| Matsuzaki, M | 1 |
| Kinugawa, T | 1 |
| Kato, M | 1 |
| Ogino, K | 1 |
| Osaki, S | 1 |
| Igawa, O | 1 |
| Hisatome, I | 1 |
| Shigemasa, C | 1 |
| Lehto, M | 1 |
| Snapinn, S | 1 |
| Dickstein, K | 2 |
| Swedberg, K | 1 |
| Nieminen, MS | 2 |
| Orn, S | 1 |
| Cleland, JG | 1 |
| Romo, M | 1 |
| Kjekshus, J | 1 |
| Dayi, SU | 1 |
| Akbulut, T | 1 |
| Akgoz, H | 1 |
| Terzi, S | 1 |
| Sayar, N | 1 |
| Aydin, A | 1 |
| Bilsel, T | 1 |
| Ciloglu, F | 1 |
| Tingberg, E | 1 |
| Ohlin, AK | 1 |
| Gottsäter, A | 1 |
| Ohlin, H | 1 |
| Xu, R | 1 |
| Zhang, Y | 1 |
| Zhang, M | 1 |
| Li, XC | 1 |
| Cai, H | 1 |
| Chen, WQ | 1 |
| Zhu, H | 1 |
| Ge, ZM | 1 |
| Zhang, W | 1 |
| Little, WC | 3 |
| Zile, MR | 1 |
| Klein, A | 1 |
| Appleton, CP | 1 |
| Kitzman, DW | 2 |
| Wesley-Farrington, DJ | 1 |
| Liu, X | 1 |
| Suzuki, H | 1 |
| Sethi, R | 1 |
| Tappia, PS | 1 |
| Takeda, N | 1 |
| Dhalla, NS | 2 |
| Simões, MV | 1 |
| Marin-Neto, JA | 1 |
| Romano, MM | 1 |
| O'Connell, JL | 1 |
| de Santi, GL | 1 |
| Maciel, BC | 1 |
| Guo, X | 1 |
| Wang, J | 1 |
| Elimban, V | 1 |
| de Simone, G | 1 |
| Devereux, RB | 2 |
| Camargo, MJ | 1 |
| Wallerson, DC | 1 |
| Sealey, JE | 1 |
| Laragh, JH | 1 |
| Pitt, B | 1 |
| Chang, P | 1 |
| Grossman, W | 1 |
| Dunlay, M | 1 |
| Timmermans, PB | 1 |
| Diaz, RJ | 1 |
| Wilson, GJ | 1 |
| Warner, JG | 1 |
| Metzger, DC | 1 |
| Wesley, DJ | 1 |
| Goodfield, NE | 1 |
| Newby, DE | 1 |
| Ludlam, CA | 1 |
| Flapan, AD | 1 |
| Ruzicka, M | 1 |
| Yuan, B | 1 |
| Anguita Sánchez, M | 1 |
| Velazquez, EJ | 1 |
| Califf, RM | 1 |
| Knowles, JW | 1 |
| Esposito, G | 1 |
| Mao, L | 1 |
| Hagaman, JR | 1 |
| Fox, JE | 1 |
| Smithies, O | 1 |
| Rockman, HA | 1 |
| Maeda, N | 1 |
| Weinberg, EO | 1 |
| Herzig, JW | 1 |
| Wittstein, IS | 1 |
| Kass, DA | 1 |
| Pak, PH | 1 |
| Maughan, WL | 1 |
| Fetics, B | 1 |
| Hare, JM | 1 |
| Davie, AP | 1 |
| Rumley, A | 1 |
| Lowe, GD | 1 |
| McMurray, JJ | 1 |
| Querejeta, R | 1 |
| Larman, M | 1 |
| Martínez Ubago, JL | 1 |
| Wachtell, K | 1 |
| Palmieri, V | 1 |
| Olsen, MH | 1 |
| Gerdts, E | 1 |
| Papademetriou, V | 1 |
| Smith, G | 1 |
| Dahlöf, B | 1 |
| Aurigemma, GP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study[NCT00043836] | Phase 2 | 20 participants | Interventional | 2002-07-31 | Completed | ||
| PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction[NCT04128891] | Phase 3 | 0 participants (Actual) | Interventional | 2020-02-01 | Withdrawn (stopped due to Funding not approved) | ||
| Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.[NCT01052272] | Phase 2/Phase 3 | 72 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Beneficio Del Bloqueo Del Sistema Renina-angiotensina Sobre la evolución clínica y el Remodelado Ventricular Tras la colocación de Una prótesis percutánea aórtica (RASTAVI)[NCT03201185] | Phase 4 | 194 participants (Actual) | Interventional | 2018-02-10 | Active, not recruiting | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 62.62 | 63.90 | 63.80 | 41.90 | 61.70 | 44.70 | 60.95 | 53.79 | 59.95 |
| Toprol XL | 62.09 | NA | 61.29 | 54.81 | 62.77 | 68.47 | 62.05 | NA | 63.02 |
Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 91.66 | 90.93 | 90.84 | 70.56 | 88.99 | 82.73 | 90.16 | 85.75 | 87.31 |
| Toprol XL | 95.74 | NA | 95.24 | NA | 95.71 | 98.16 | 97.6 | NA | 95.16 |
Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 34.01 | 32.83 | 32.53 | 40.99 | 33.70 | 47.25 | 34.99 | 39.97 | 34.47 |
| Toprol XL | 35.98 | NA | 36.53 | NA | 35.89 | 30.97 | 36.72 | NA | 35.13 |
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 0.61 | 0.53 | 0.62 | 0.67 | 0.65 | 0.65 | 0.65 | 0.61 | 0.64 |
| Toprol XL | 0.61 | NA | 0.6 | 0.53 | 0.60 | 0.55 | 0.59 | NA | 0.62 |
Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 4.76 | 5.02 | 4.51 | 4.15 | 4.46 | 4.61 | 4.43 | 4.72 | 4.52 |
| Toprol XL | 4.69 | NA | 4.85 | 5.74 | 4.79 | 5.02 | 4.77 | NA | 4.59 |
Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | EDV/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 2.27 | 2.58 | 2.38 | 1.56 | 2.26 | 1.83 | 1.95 | 1.73 | 2.17 |
| Toprol XL | 2.12 | NA | 2.08 | NA | 2.24 | 2.28 | 2.26 | NA | 2.25 |
Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent/%Systolic interval (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 87.94 | 115.07 | 45.90 | 37.2 | 87.85 | 52.95 | 88.11 | 67.53 | 79.94 |
| Toprol XL | 82.55 | NA | 78.68 | NA | 80.04 | 88.34 | 79.29 | NA | 85.18 |
LVEF is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 56.36 | 56.82 | 42.62 | 52.37 | 39.88 | 56.33 | NA | 51.70 | 54.17 |
| Candesartan Cilexetil and Allopurinol | 52.68 | 57.28 | NA | 56.11 | 54.46 | 57.82 | 56.17 | 55.79 | 54.40 |
| Ramipril | 52.19 | 54.20 | 64.98 | 52.76 | 52.13 | 55.02 | 51.27 | 57.18 | 50.73 |
| Ramipril and Allopurinol | 53.37 | 52.80 | NA | 51.74 | 34.89 | 54.05 | NA | 55.59 | NA |
LVEDV/BSA: As an indicator of heart size, the blood volume of the heart is related to the body size. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 78.06 | 78.60 | 93.57 | 85.44 | 90.20 | 82.74 | NA | 84.28 | 76.65 |
| Candesartan Cilexetil and Allopurinol | 79.03 | 78.01 | NA | 79.75 | 63.1 | 84.95 | 75.27 | 79.72 | 75.05 |
| Ramipril | 73.03 | 74.10 | 73.23 | 75.34 | 81.19 | 75.28 | 71.99 | 70.46 | 48.68 |
| Ramipril and Allopurinol | 78.52 | 86.13 | NA | 83.95 | 108.25 | 67.96 | NA | 71.63 | NA |
LVESV/BSA: The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 35.26 | 35.26 | 53.87 | 42.27 | 54.04 | 37.76 | NA | 41.72 | 35.13 |
| Candesartan Cilexetil and Allopurinol | 39.49 | 34.15 | NA | 36.07 | 28.74 | 37.18 | 32.99 | 35.99 | 34.22 |
| Ramipril | 36.20 | 34.77 | 25.64 | 36.82 | 39.42 | 35.30 | 35.23 | 31.17 | 23.98 |
| Ramipril and Allopurinol | 37.91 | 42.88 | NA | 42.34 | 70.48 | 30.39 | NA | 31.56 | NA |
LVED Mass/LVEDV: As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 0.95 | 0.83 | 0.67 | 0.78 | 0.70 | 0.79 | NA | 0.80 | 0.64 |
| Candesartan Cilexetil and Allopurinol | 0.87 | 0.82 | NA | 0.86 | 0.68 | 0.80 | 0.69 | 0.82 | 0.69 |
| Ramipril | 0.92 | 0.87 | 0.75 | 0.84 | 0.81 | 0.79 | 0.95 | 0.84 | 0.93 |
| Ramipril and Allopurinol | 0.86 | 0.71 | NA | 0.72 | 0.57 | 0.83 | NA | 0.80 | NA |
LVED Radius/Wall thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 3.14 | 3.39 | 4.14 | 3.68 | 4.10 | 3.71 | NA | 3.58 | 4.04 |
| Candesartan Cilexetil and Allopurinol | 3.45 | 3.63 | NA | 3.42 | 3.90 | 3.56 | 4.24 | 3.56 | 4.29 |
| Ramipril | 3.23 | 3.32 | 3.42 | 3.43 | 3.44 | 3.60 | 2.92 | 3.46 | 3.12 |
| Ramipril and Allopurinol | 3.57 | 4.04 | NA | 4.01 | 4.57 | 3.60 | NA | 3.61 | NA |
By identifying three points in three different planes in the heart muscle, the maximum shortening is the average of the difference between the distance between these three points at the end of filling of the heart and the end of contraction divided by the length at the end of filling times 100. The maximum shortening is a three dimensional analysis. The higher values indicate a healthy heart. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent of length at end of filling (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,17,18) | Month 6(n=14,11,10,12) | Month 9(n=1,2,0,0) | Month 12(n=11,11,10,10) | Month 15(n=3,2,1,1) | Month 18(n=10,12,7,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 16.68 | 17.50 | 19.08 | 17.13 | 16.28 | 17.55 | NA | 16.62 | 20.38 |
| Candesartan Cilexetil and Allopurinol | 16.00 | 18.50 | NA | 18.51 | 16.36 | 17.52 | 17.89 | 17.85 | 16.59 |
| Ramipril | 15.81 | 16.88 | 18.43 | 14.57 | 17.06 | 17.26 | 16.68 | 15.67 | 13.70 |
| Ramipril and Allopurinol | 15.84 | 18.72 | NA | 17.96 | 14.22 | 17.46 | NA | 17.52 | NA |
The Peak Early Filling Rate Normalized to EDV is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | 1/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 2.01 | 2.02 | 1.13 | 1.90 | 1.48 | 1.93 | NA | 1.65 | 1.10 |
| Candesartan Cilexetil and Allopurinol | 2.0 | 1.98 | NA | 1.77 | 2.28 | 2.05 | 2.50 | 1.82 | 2.15 |
| Ramipril | 1.93 | 1.74 | 2.50 | 1.80 | 2.02 | 1.91 | 1.69 | 2.05 | 1.34 |
| Ramipril and Allopurinol | 2.11 | 2.03 | NA | 1.93 | 1.56 | 1.89 | NA | 1.88 | NA |
4 reviews available for losartan and Left Ventricular Dysfunction
| Article | Year |
|---|---|
[Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2003 |
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Fai | 2003 |
Management of hypertension and heart failure with AT1 receptor blockade.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiac Output, Low; Clinical Trial | 2001 |
Hypertensive pulmonary oedema is due to diastolic dysfunction.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Diastole; Echocardiography, Doppler; Heart Fa | 2001 |
19 trials available for losartan and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2016 |
[Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiotonic Agents; C | 2009 |
Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication.
Topics: Adult; Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2011 |
Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.
Topics: Aged; Angiotensin Receptor Antagonists; Chronic Disease; Drug Synergism; Drug Therapy, Combination; | 2011 |
Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2012 |
Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2012 |
Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Heart Failure; Humans; Hyperventil | 2004 |
Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; Captopr | 2005 |
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Death, Sudden, Cardiac; Female; Follo | 2005 |
Long-term combined therapy with losartan and an angiotensin-converting enzyme inhibitor improves functional capacity in patients with left ventricular dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Exercise Test; Ex | 2005 |
Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2006 |
Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Female; Humans; Hypertension; | 2006 |
Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction.
Topics: Antihypertensive Agents; Blood Pressure; Diastole; Diuretics; Double-Blind Method; Echocardiography, | 2006 |
Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS).
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Doub | 1996 |
Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Diastole; Double-Blind Met | 1999 |
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 1999 |
Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cross-Over Studies; Doub | 2001 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Biopsy; Blood Pressure; Cluster Analysis; Collagen | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Topics: Antihypertensive Agents; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Hypertens | 2002 |
27 other studies available for losartan and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
Impaired right and left ventricular function and relaxation induced by pulmonary regurgitation are not reversed by tardive antifibrosis treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography; Fibrosis | 2021 |
Echocardiographic Strain Analysis for the Early Detection of Myocardial Structural Abnormality and Initiation of Drug Therapy in a Mouse Model of Dilated Cardiomyopathy.
Topics: Animals; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Disease Models, Animal; Echocardiography; | 2017 |
T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Contrast Media; Disease Models, Animal; Dose-Respo | 2014 |
Activation of the Cardiac Renin-Angiotensin System in High Oxygen-Exposed Newborn Rats: Angiotensin Receptor Blockade Prevents the Developmental Programming of Cardiac Dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cardiomegaly; Disease Models, An | 2016 |
Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line; Connective Tissue Growth Factor; Fibros | 2017 |
Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Atorvastatin; Drug Thera | 2008 |
Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Echocardiography; Injections | 2009 |
Association of candesartan vs losartan with all-cause mortality in patients with heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cause | 2011 |
[The HEAAL study].
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Losartan; Multicenter Studies as Top | 2010 |
Candesartan vs losartan and mortality in patients with heart failure.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Europe; Guideline Adherence; H | 2011 |
Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure.
Topics: Angiotensin II; Animals; Body Weight; Brain; Brain Stem; Electrocardiography; Heart; Heart Failure; | 2011 |
[Addition of an angiotensin II receptor blocker to maximal dose of ACE inhibitors in heart failure].
Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2002 |
Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Aldosterone; Angiotensin Receptor Antagonists; Angio | 2002 |
[Suboptimal results of Optimaal: treatment with ACE inhibitors remains the preferred therapy in patients with left ventricular dysfunction after acute myocardial infarct]].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause of Death; Female; Humans; Length of Stay; | 2002 |
The OPTIMAAL study, not so optimal: the lessons of LIFE, RENAAL and IDNT.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; | 2003 |
[Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2005 |
Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetic Angiopa | 2006 |
Transient left ventricular dysfunction due to stress-induced cardiomyopathy.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; | 2007 |
Both enalapril and losartan attenuate sarcolemmal Na+-K+-ATPase remodeling in failing rat heart due to myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease | 2008 |
Midwall left ventricular performance in salt-loaded Dahl rats: effect of AT1 angiotensin II inhibition.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Echocardiogr | 1995 |
Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Coronary Circul | 1997 |
Blockade of AT(1) receptors and Na(+)/H(+) exchanger and LV dysfunction after myocardial infarction in rats.
Topics: Amiloride; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Blood Volume; Drug Combination | 1999 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
All that glitters is not gold.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captopril; Heart Failure; Humans; | 2000 |
Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Enalapril; Furosemide; Guanylate Cyc | 2001 |
Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardiomyopath | 2001 |